Lukas Scheibler
Company: Apellis Pharmaceuticals
Job title: Chief Innovation Officer
Seminars:
Panel Discussion: What Does the Future Hold for Complement Therapies? 3:00 pm
This is your opportunity to chat directly with the speakers and voice your own thoughts and research on the future of complement therapiesRead more
day: Day Two
Targeted C3 Therapy, Pegcetacoplan, has the Potential to Elevate the Standard of Care in PNH 2:30 pm
day: Day Two
Targeted C3 Therapy, Pegcetacoplan, has the Potential to Elevate the Standard of Care in PNH 4:00 pm
Targeted C3 Therapy, Pegcetacoplan, has the Potential to Elevate the Standard of Care in PNH 4:00 pm